After 8 weeks of treatment, the numbers of naïve and effector/memory CD8 and CD4 T cells are markedly increased, while the expression of immunoinhibitory PD-1 and CTLA-4 is significantly reduced on T cells in CLL patients (Long et al., 2017; Cadot et al., 2020). This evidence concerns the gene CD8A and B-cell chronic lymphocytic leukemia.